Oncotype Dx Colon Cancer test is based on mRNA expression of 12 target genes, and was validated in a large clinical trial of primary CRC cases, finding clinical utility when used as a complement to T stage and mismatch repair status, specifically for patients who have T3, MMR-proficient, stage II disease [17, 18]. The gene discussed is MRC1; the disease is malignant colon neoplasm.